EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements

Boehringer IngelheimBoehringer Ingelheim announced that it will dedicate EUR 50 million to a new initiative called "Boehringer Ingelheim Social Engagements". The program provides financing for impact to social businesses in vulnerable communities through non-traditional financing options, combined with a partnering approach.

"Start-ups often need more than just funding, so we aim to provide financial and non-financial support together with complementary partners. Boehringer Ingelheim Social Engagements is dedicating 50 million Euros to help scale up solutions of social businesses to create systemic change," says Michael Schmelmer, Member of the Board of Managing Directors at Boehringer Ingelheim, announcing the initiative on the occasion of the "Making More Health Together 2021" convention.

Boehringer Ingelheim Social Engagements is an extension of Boehringer Ingelheim's flagship initiative, Making More Health (MMH). MMH was jointly created by Boehringer Ingelheim and Ashoka, the world's largest network of social entrepreneurs. This long-term partnership focuses on connecting innovative solutions with business expertise to address complex healthcare challenges for people, animals, and their communities.

One initiative is the Making More Health Business Accelerator, a program targeted towards social entrepreneurs in Sub-Saharan Africa. Since 2018, it provides financial means, in form of donations, and business expertise support through Boehringer Ingelheim employee engagement. Until today, 12 social businesses have been supported, and many have progressed to a stage, where more substantial funding is necessary. Boehringer Ingelheim Social Engagements is now stepping up to provide financial support beyond typical corporate donations. With this, Boehringer Ingelheim also wants to enable additional funding from other investors and engage with likeminded partners to catalyze expertise. This closes a critical financing gap for these social businesses.

After an initial start-up phase in 2022, Boehringer Ingelheim Social Engagements will extend its focus beyond the Making More Health Business Accelerator in Sub-Sahara Africa, by targeting additional projects globally.

Making More Health has committed to positively impact the lives and health of 50 million people and engage 20,000 Boehringer Ingelheim employees by 2030. Boehringer Ingelheim Social Engagements will be key to achieving this objective. An overview with case studies on the Making More Health Accelerator, as well as local projects can be found here.

About Making More Health

Making More Health (MMH) is a long-term global initiative of Boehringer Ingelheim in collaboration with Ashoka, the world-largest network of social entrepreneurs. It focuses on co-creation with the aim of creating shared value to achieve better solutions for today's global challenges, by integrating innovative social entrepreneurial thinking into business practices. MMH provides sustainable and holistic solutions to communities worldwide since 2010. Learn more at www.makingmorehealth.com

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Most Popular Now

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...